COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was identified in Wuhan, China, in December 2019. It has since spread worldwide, leading to an ongoing pandemic that has caused millions of deaths and led to broad societal lockdowns. It’s widely considered one of the main health crisis for a century.
The virus has evolved into multiple different mutations, some of which have turned out to be more transmissible than the original strains with the potential to escape the first generation of vaccines.
The COVID-19 outbreak led to a global race to develop therapies and vaccines. Currently there are more than 1200 therapies under investigation / development and more than 300 vaccines.
Airfinity was the first company to build a science intelligence platform dedicated to COVID-19 supported by a large dedicated expert team who have followed the pandemic from the beginning. We provide global coverage of four related areas:
Macro-economic related risks and policies
Get immediate answers to your critical C-19 questions with access to Airfinity’s platform - a comprehensive real time data set, analytics and forecasting engine relied upon by multiple government agencies, medical organisations, top hedge funds, pharma companies and researchers worldwide.
Common questions Airfinity can help you answer:
When will a working vaccine be widely available? When will lockdown restrictions ease in specific countries? Which vaccines and treatments show most promise? Where are the major risks in global supply and production capacity? What are the real time insights derived from the scientific data and opinions of experts?
Our platform includes:
Detailed insights into the underlying science per vaccine or therapeutic candidate
Status on clinical trials and competitor comparisons
Experts’ opinions based on conferences and social media
Funding per candidate information
Analysis of vaccine and treatment production capability and supply chain dynamics
Monitoring of active distribution agreements
Real time forecasting of infection rates
Predictive modelling on country level normalisation or openings
Customisable, machine learning driven simulations and risk indicators
Global coverage including dedicated native speaking teams in Russia and China
We deliver critical data, information and insights to global decision makers across pharmaceuticals, med- and biotech companies, governments, corporates and investors.
Our experts will:
Complete the form to schedule your demo.